Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up

BACKGROUND: Lenvatinib is a standard first-line treatment for progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), but real-world outcomes over extended follow-up and prognostic factors remain insufficiently characterized. METHODS: We retrospectively analyzed 97 patients with progressive RAI-R DTC treated with lenvatinib at a single institution between 2015 and 2024. Patients with anaplastic or medullary thyroid carcinoma and those treated for less than six months were excluded. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and prognostic factors were assessed using Cox proportional hazards models. RESULTS: Median age at treatment initiation was 68 years, and 38% of patients had bone metastases. With a median follow-up of 36 months, median PFS and OS were 25 months (95% confidence interval [CI], 21-31) and 59 months (95% CI, 45-82), respectively. The objective response rate was 58%, and the disease control rate was 97%. Multivariate analysis identified older age as an independent predictor of shorter PFS (Hazard ratio [HR] 1.34 per decade of age, p<0.01) and OS (HR 1.63 per decade of age, p<0.005). Bone metastasis was independently associated with worse OS (HR 2.25, p<0.05) but not PFS. Receiver operating characteristic analyses suggested age cutoffs of approximately 70 years. Bone metastasis was associated with significantly poorer OS among older patients. CONCLUSIONS: Lenvatinib provided durable disease control in patients with RAI-R DTC. Older age at treatment initiation and bone metastasis were independent determinants of survival and may help guide risk stratification and treatment timing in clinical practice.

Authors

Institutions

Publication Details

Journal
European Thyroid Journal
Published
2026-11-12
DOI
https://doi.org/10.1530/etj-26-0231
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up

Kiminori Sugino, Kiyomi Yamada Hames, Ritsuko Okamura, Kenichi Matsuzu et al.
European Thyroid Journal
Thyroid Cancer Diagnosis and Treatment
article

Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up

Kiminori Sugino, Kiyomi Yamada Hames, Ritsuko Okamura, Kenichi Matsuzu, Akifumi Suzuki, Chie Masaki, Kana Yoshioka, Junko Akaishi, Chisato Tomoda, Wataru Kitagawa, Yoshiyuki Saito, Koichi Ito
article en

Abstract

BACKGROUND: Lenvatinib is a standard first-line treatment for progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), but real-world outcomes over extended follow-up and prognostic factors remain insufficiently characterized. METHODS: We retrospectively analyzed 97 patients with progressive RAI-R DTC treated with lenvatinib at a single institution between 2015 and 2024. Patients with anaplastic or medullary thyroid carcinoma and those treated for less than six months were excluded. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and prognostic factors were assessed using Cox proportional hazards models. RESULTS: Median age at treatment initiation was 68 years, and 38% of patients had bone metastases. With a median follow-up of 36 months, median PFS and OS were 25 months (95% confidence interval [CI], 21-31) and 59 months (95% CI, 45-82), respectively. The objective response rate was 58%, and the disease control rate was 97%. Multivariate analysis identified older age as an independent predictor of shorter PFS (Hazard ratio [HR] 1.34 per decade of age, p<0.01) and OS (HR 1.63 per decade of age, p<0.005). Bone metastasis was independently associated with worse OS (HR 2.25, p<0.05) but not PFS. Receiver operating characteristic analyses suggested age cutoffs of approximately 70 years. Bone metastasis was associated with significantly poorer OS among older patients. CONCLUSIONS: Lenvatinib provided durable disease control in patients with RAI-R DTC. Older age at treatment initiation and bone metastasis were independent determinants of survival and may help guide risk stratification and treatment timing in clinical practice.

European Thyroid Journal
Ito Hospital (JP)
Good health and well-being
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon